Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

30

Revenue 2017

Botox/Neuromodulator

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.

CGRP migraine drugs need prior approval for use, recommends ICER

CGRP migraine drugs need prior approval for use, recommends ICER that it offered value for money, but only if other migraine prevention options such as Allergan’s Botox and anti-epilepsy drugs such as topiramate had been exhausted.

ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line

ICER says price of Amgen/Novartis’ Aimovig is OK - if used last-line That includes drugs such as Allergan’s Botox, which costs around $3, 500 per year, as well as certain anti-epilepsy drugs such as topiramate.

Novartis, Amgen set low price for first CGRP migraine drug

Novartis, Amgen set low price for first CGRP migraine drug medicines such as the anticonvulsant topiramate or Allergan's Botox. ... As a migraine treatment Botox costs around $3, 500 per year, and analysts predict that the annual price for Aimovig will drop to around $5, 000 with rebates and discounts.

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more Despite this embarrassing failure, yesterday’s Q1 results were encouraging, with revenues up 2.8% thanks to growth in Botox, Vraylar and regenerative medicines.

Allergan’s oral migraine drug closer to US filing

Allergan’s oral migraine drug closer to US filing medicines such as the anticonvulsant topiramate or Allergan's biggest and best-known product, Botox.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Why we need to improve diverse representation in clinical trials
Diversity in clinical trials: The powerful need to improve it! “One size fits all” is rapidly becoming an outdated concept in modern-day life, and medical research is no exception. Without...

Infographics